Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:8012512rdf:typepubmed:Citationlld:pubmed
pubmed-article:8012512lifeskim:mentionsumls-concept:C0008372lld:lifeskim
pubmed-article:8012512lifeskim:mentionsumls-concept:C0268311lld:lifeskim
pubmed-article:8012512lifeskim:mentionsumls-concept:C2697382lld:lifeskim
pubmed-article:8012512pubmed:issue2lld:pubmed
pubmed-article:8012512pubmed:dateCreated1994-7-26lld:pubmed
pubmed-article:8012512pubmed:abstractTextA 58-year-old Japanese man was admitted to our hospital with appendicitis and marked unconjugated hyperbilirubinemia (11.6 mg/dl). The jaundice worsened following appendectomy, and the direct-reacting bilirubin increased, probably due to the ceftizoxime administered postoperatively. Bilirubin diglucuronide was the main component of the serum direct-reacting bilirubin (51%) in serum measured by liquid chromatography. Because the discontinuation of ceftizoxime did not markedly improve the jaundice, epomediol, 200 mg tid, was administered orally. There was a marked decrease of serum bilirubin with an increase in the delta bilirubin/(conjugated bilirubin + delta bilirubin) ratio. After improvement of jaundice to below the pre-surgical level (4.4 mg/dl), we analyzed the duodenal bile for bilirubin fractions; those showed a marked reduction in bilirubin diglucuronide and a marked increase in bilirubin monoglucuronide, which was consistent with type II Crigler-Najjar syndrome. A marked increase of bilirubin diglucuronide in serum of this patient during cholestasis suggests that bilirubin conjugation proceeds in this syndrome when excretion of conjugated bilirubin decreases.lld:pubmed
pubmed-article:8012512pubmed:languageenglld:pubmed
pubmed-article:8012512pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8012512pubmed:citationSubsetIMlld:pubmed
pubmed-article:8012512pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8012512pubmed:statusMEDLINElld:pubmed
pubmed-article:8012512pubmed:monthAprlld:pubmed
pubmed-article:8012512pubmed:issn0944-1174lld:pubmed
pubmed-article:8012512pubmed:authorpubmed-author:YamamotoTTlld:pubmed
pubmed-article:8012512pubmed:authorpubmed-author:AdachiYYlld:pubmed
pubmed-article:8012512pubmed:authorpubmed-author:KamauPPlld:pubmed
pubmed-article:8012512pubmed:authorpubmed-author:KamisakoTTlld:pubmed
pubmed-article:8012512pubmed:authorpubmed-author:KagitaAAlld:pubmed
pubmed-article:8012512pubmed:issnTypePrintlld:pubmed
pubmed-article:8012512pubmed:volume29lld:pubmed
pubmed-article:8012512pubmed:ownerNLMlld:pubmed
pubmed-article:8012512pubmed:authorsCompleteYlld:pubmed
pubmed-article:8012512pubmed:pagination214-7lld:pubmed
pubmed-article:8012512pubmed:dateRevised2004-11-17lld:pubmed
pubmed-article:8012512pubmed:meshHeadingpubmed-meshheading:8012512-...lld:pubmed
pubmed-article:8012512pubmed:meshHeadingpubmed-meshheading:8012512-...lld:pubmed
pubmed-article:8012512pubmed:meshHeadingpubmed-meshheading:8012512-...lld:pubmed
pubmed-article:8012512pubmed:meshHeadingpubmed-meshheading:8012512-...lld:pubmed
pubmed-article:8012512pubmed:meshHeadingpubmed-meshheading:8012512-...lld:pubmed
pubmed-article:8012512pubmed:meshHeadingpubmed-meshheading:8012512-...lld:pubmed
pubmed-article:8012512pubmed:meshHeadingpubmed-meshheading:8012512-...lld:pubmed
pubmed-article:8012512pubmed:year1994lld:pubmed
pubmed-article:8012512pubmed:articleTitleType II crigler-Najjar syndrome with intrahepatic cholestasis.lld:pubmed
pubmed-article:8012512pubmed:affiliationSecond Department of Internal Medicine, Kinki University School of Medicine, Osaka, Japan.lld:pubmed
pubmed-article:8012512pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:8012512pubmed:publicationTypeCase Reportslld:pubmed